Your browser doesn't support javascript.
loading
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above.
Li, Zhuo-Pei; Shi, Yun-Feng; Hou, Li-Hua; Jin, Peng-Fei; Ma, Shi-Hua; Pan, Hong-Xing; Zhang, Jin-Long; Shan, Yong-Mei; Huang, Hai-Tao; Wu, Shi-Po; Du, Pan; Wang, Xue; Wang, Li-Li; Wang, Rui-Jie; Wang, Ying; Wang, Xue-Wen; Zhu, Feng-Cai; Li, Jing-Xin.
Affiliation
  • Li ZP; School of Public Health, Nanjing Medical University, Nanjing, P.R. China.
  • Shi YF; NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China.
  • Hou LH; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R. China.
  • Jin PF; NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China.
  • Ma SH; Guanyun County Center for Disease Control and Prevention, Guanyun, P.R. China.
  • Pan HX; NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China.
  • Zhang JL; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R. China.
  • Shan YM; Guanyun County Center for Disease Control and Prevention, Guanyun, P.R. China.
  • Huang HT; CanSino Biologics Inc, Tianjin, P.R. China.
  • Wu SP; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R. China.
  • Du P; Vazyme Biotech Co. Ltd, Nanjing, P.R. China.
  • Wang X; Basic Medical Science School, Zhengzhou University, Zhengzhou, P.R. China.
  • Wang LL; CanSino Biologics Inc, Tianjin, P.R. China.
  • Wang RJ; Guanyun County Center for Disease Control and Prevention, Guanyun, P.R. China.
  • Wang Y; CanSino Biologics Inc, Tianjin, P.R. China.
  • Wang XW; CanSino Biologics Inc, Tianjin, P.R. China.
  • Zhu FC; Shanghai Canming Medical Technology Co Ltd, Shanghai, P.R. China.
  • Li JX; School of Public Health, Nanjing Medical University, Nanjing, P.R. China.
Expert Rev Vaccines ; 21(12): 1843-1849, 2022 12.
Article de En | MEDLINE | ID: mdl-36048417
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins contre la COVID-19 / COVID-19 Type d'étude: Clinical_trials Limites: Adult / Humans Langue: En Journal: Expert Rev Vaccines Sujet du journal: ALERGIA E IMUNOLOGIA Année: 2022 Type de document: Article Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins contre la COVID-19 / COVID-19 Type d'étude: Clinical_trials Limites: Adult / Humans Langue: En Journal: Expert Rev Vaccines Sujet du journal: ALERGIA E IMUNOLOGIA Année: 2022 Type de document: Article Pays de publication: Royaume-Uni